22
Participants
Start Date
May 31, 2006
Primary Completion Date
August 31, 2008
Study Completion Date
July 31, 2009
Bevacizumab
Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
verteporfin photodynamic therapy reduced fluence
Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].
verteporfin photodynamic therapy standardfluence
Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].
California Retina Consultants, Santa Barbara
California Retina Consultants, Bakersfield
Collaborators (1)
Novartis
INDUSTRY
California Retina Consultants
OTHER